STUDY QUESTION: Are preconception urinary concentrations of phthalates and phthalate alternatives associated with diminished early stage embryo quality in couples undergoing IVF?
high or transferrable blastocyst quality, but the observed associations were not consistent across blastocyst quality measures or between sexspecific and couples-level models. All models were adjusted for age of both partners, urinary metabolite concentrations of female partners and male infertility status, while models of blastocysts were additionally adjusted for embryo quality at cleavage stage.
Introduction
Endocrine disrupting compounds (EDCs) have received considerable attention due to their potential to disrupt hormonal function and their association with a range of adverse reproductive health consequences in humans (Diamanti-Kandarakis et al., 2009; Vandenberg et al., 2012) . Phthalates, one class of EDCs, are used in a large variety of commercial products, such as medical products, food packaging, personal care products and solvents (Jurewicz and Hanke, 2011) . Because they are not chemically bound to products, phthalates are easily released into the environment resulting in chronic and widespread human exposure in the USA (CDC, 2015) and globally (Ha et al., 2014; Polanska et al., 2014 , Sakhi et al., 2014 Bai et al., 2015) . The potential of phthalates to adversely influence reproductive health has been well documented (Mariana et al., 2016) . Similar to other EDCs, phthalates display antiandrogenic properties (Chauvigne et al., 2009; Clewell et al., 2010 Clewell et al., , 2013 . In addition, both male and female preconception phthalate exposure has been associated with a range of adverse pregnancy and birth outcomes (Toft et al., 2012; Buck Louis et al., 2014; Bae et al., 2015; Smarr et al., 2015) . The recent rise in the use of replacement phthalates and phthalate alternative compounds is a developing public health concern. Human exposure to these compounds has increased over the past decade (CDC, 2015) ; however, there is limited research on their role in male and female reproductive health.
To our knowledge, only one cohort has investigated the association of preconception phthalate concentrations with embryo development. Studies from the Environmental and Reproductive Health (EARTH) have reported that male partner preconception urinary concentrations of select phthalate metabolites were associated with decreased odds of implantation and live birth among couples seeking fertility treatment, while female partner phthalate metabolite concentrations were associated with lower mature and overall oocyte yield as well as decreased probability of clinical pregnancy and live birth; however, no associations were observed with embryo quality at the cleavage stage (Day 3) (Dodge et al., 2015; Hauser et al., 2016) . These results suggest that parental contributions to early life development may appear after Day 3, the cleavage stage, when the embryo transitions away from maternal control and zygotic genome activation occurs.
In light of the compelling evidence from these previous studies, we conducted a prospective study to examine the relationship of preconception concentrations of phthalates and phthalate alternatives on in vitro embryo quality through the blastocyst stage of development.
Materials and Methods

Study population
The study population comprised 761 oocytes from the first 50 couples recruited as part of the Sperm Environmental Epigenetics and Development Study (SEEDS), a prospective cohort designed to investigate parental preconception exposures to EDCs and early life development. All couples were recruited from the Baystate Medical Center Fertility Center in Springfield, MA, which primarily serves western Massachusetts and northern Connecticut. Couples were included if the male partners were 18-55 years old without vasectomy, if female partners were 40 years or younger with expected delivery at Baystate Medical Center, and if fresh ejaculate sperm were used for IVF, including ICSI. Relevant data on demographics, lifestyle factors and medical history were collected by clinic personnel from both partners during the course of an IVF cycle. Prior to sample collection, each partner completed an intake questionnaire regarding lifestyle factors. Each couple contributed only one cycle to the study.
Written consent was obtained by attending physicians from eligible males and females interested in study participation. This study was approved by the Institutional Review Boards at Baystate Medical Center and at the University of Massachusetts Amherst.
Urinary biomarkers measurement
A spot urine sample was collected from both male and female partners in a sterile polypropylene collection cup on the same day as semen sample procurement and oocyte retrieval. Urine samples were vortexed, divided into several aliquots and stored at −80°C before being shipped overnight on dry ice to the CDC's National Center for Environmental Health, where the urinary biomarkers were quantified via enzymatic deconjugation, solidphase extraction, separation and analyses using liquid chromatography mass spectrometry (Silva et al., 2013) .
In total, 17 urinary metabolites were quantified: mono(2-ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono (2-ethyl-5-oxohexyl) phthalate (MEOHP), mono (2-ethyl-5-carboxypentyl) phthalate (MECPP), mono-carboxy-isooctyl phthalate (MCOP), monoisononyl phthalate (MNP), monobenzyl phthalate (MBzP), mono (3-carboxypropyl) phthalate (MCPP), mono-carboxy-isononyl phthalate (MCNP), mono-n-butyl phthalate (MBP), mono-3-hydroxybutyl phthalate (MHBP), mono-isobutyl phthalate (MiBP), mono-hydroxyisobutyl phthalate (MHiBP), monoethyl phthalate (MEP), monomethyl phthalate (MMP), cyclohexane-1,2-dicarboxylic acid-monocarboxy isooctyl ester (MCOCH) and cyclohexane-1,2-dicarboxylic acid-mono(hydroxy-isononyl) ester (MHINCH). The limits of detection (LODs) ranged from 0.2 to 0.6 ng/ml, depending on the metabolite. Specific gravity (SG) was measured at room temperature using a digital handheld refractometer (Atago Co., Ltd., Tokyo, Japan).
Embryo quality assessment
Embryos were evaluated on a five-point scale (1 being the best and 5 being the worst quality) on Days 3 and 5 post-insemination, during the cleavage stage and blastocyst stage, respectively. A separate category was reserved for all arrested embryos at both time points. At the cleavage stage, embryos were evaluated morphologically for the presence or absence of blastomere multinucleation, symmetry, cell number and amount of fragmentation using the Veeck system (Veeck, 1988) . For example, embryos with eight cells, no multinucleated blastomeres and no fragmentation are considered Grade 1, while embryos with seven cells, no multinucleated blastomeres and <10% fragmentation are Grade 2 and embryos with six cells, no multimucleated blastomeres and 20% fragmentation are Grade 4. At the blastocyst stage, embryos were evaluated for the developmental stage including the expansion of blastocoel and quality of trophectoderm and inner cell mass. For example, embryos at blastocyst stage with full expansion, hatching or hatched with large compact inner cell mass and well-defined cohesive trophectoderm with many cells are considered Grade 1, while an expanded blastocyst with a large, mostly compacted inner cell mass and medium number of trophectoderm cells is classified as Grade 2 and blastocysts lacking full expansion or having an inner cell mass comprised a small number of cells or a small number of non-uniform trophectoderm cells are Grade 4 quality. At both time points, Grades 1 and 2 were classified as high-quality embryos, similar to that in a previously published study (Dodge et al., 2015) , while at Day 5, Grades 1-4 were additionally classified as transferrable quality.
Statistical analysis
Urinary biomarker concentrations below the LOD were assigned a value of the LOD divided by the square root of two. All urinary phthalate measurements were corrected for SG and log-transformed. SG-correction followed the formula Pc = P[(SGm−1)/(SG−1)], where Pc is the SG-corrected urinary metabolite concentration (ng/ml), P is the measured metabolite concentration, SGm is the sex-specific median SG, and SG is the specific gravity of the urine sample. Geometric means and selected percentiles were calculated for both male and female partners to describe the distributions of SG-adjusted urinary phthalate and phthalate alternative metabolites. Wilcoxon paired signed rank test and Fisher's exact test were used to test for differences in distribution of demographics, where applicable.
For embryo-level outcomes, general estimating equations (GEE), using a binomial distribution and exchangeable correlation structure, were used to account for the correlated structure of the embryo data within couples and to estimate the associations between partner urinary concentrations of phthalates and phthalate alternatives and embryo development measures through 5-day post-insemination. Log-transformed and SG-corrected urinary biomarker concentrations were fitted as continuous values when the majority of the population had levels above the LOD and as dichotomous values based on the LOD when majority of the population had levels below the LOD. Fertilization, high quality and transferable quality statuses for each embryo were fitted as a dichotomous outcome. All odds ratios (ORs) represent the impact of a one unit increase in log-transformed paternal urinary metabolite concentration, except for MCOCH and MHINCH, where the ORs represent above or below the LOD (0.4 and 0.5 ng/ml, respectively). Two types of models were fitted: sex-specific and couple-level. The sex-specific models included only the covariates of specific partners, male or female, but not both, whereas couple-level models adjusted for covariates and metabolite concentrations from both partners. Inclusion of covariates in multivariable models was based on the biological plausibility and statistical significance (P < 0.1) in bivariate models of embryo quality. Covariates considered for inclusion were age, BMI, race, infertility status, alcohol use and smoking status.
For additional sensitivity analyses, we restricted the embryos under analysis to mature oocytes, fertilized oocytes (for outcomes at Days 3 and 5), embryos of sufficient quality to be cultured past cleavage stage (for blastocyst stage embryos) or oocytes from non-smokers. Finally, to crossvalidate our GEE model, we fitted (i) Poisson models at the couple level, aggregating the number of embryos and using the total number of embryos at Day 3 as an offset and (ii) two-level mixed models specifying random intercepts and binomial distribution.
Analysis was performed with R (v3.3.0) using the 'gee' package (v4.13.19) for GEE models. Statistical significance was defined as P-values < 0.05.
Results
Select demographics for this study population of 50 heterosexual couples seeking fertility treatment are shown in Table I . Compared to female partners, the male partners were 1.7 years older on average and more likely to be older than 40 years, whereas female partners were more likely to be between 30 and 40 years of age. The majority of the participants in our sample identified as non-Hispanic white, with only four males and two females identified as non-white. The mean body weight for males and females were 28.8 and 28.9, respectively, with 78% of males and 66% of females classified as overweight (BMI 25-29.9) or obese (BMI ≥ 30). Race and BMI were not found to be associated with embryo quality and thus were not included in the multivariable models.
The majority of the couples at the fertility clinic had at least one partner diagnosed with subfertility or infertility (Table I ). In our sample, 20 couples had a diagnosis of female factor alone (40%), 6 couples had male factor alone (12%), 8 couples had both (16%) and 16 couples had unexplained infertility (32%). Based on semen quality according to the WHO reference values (Cooper et al., 2010) , 14 males were considered infertile. Females were diagnosed infertile based on a variety of known, nonexclusive, conditions. Of the 28 females classified as infertile, 10 had polycystic ovary syndrome, 9 were anovulatory, 7 had diminished ovarian reserve, 5 had tubal factor, 1 had endometriosis and 6 had other diagnoses.
Descriptive statistics of couple-specific oocyte and embryo data are also presented in Table I . A total of 761 oocytes were retrieved, yielding an average of 15.2 oocytes per couple per cycle. Of the 761 oocytes, 599 were mature at the time of insemination, 449 were fertilized and 423 progressed to the cleavage stage. Three days after conventional IVF or ICSI, 261 of the oocytes had developed into high-quality cleavage stage embryos, while 391 embryos were of sufficient quality to be cultured until Day 5. Of those 391 embryos, 47 developed to high-quality blastocysts at Day 5; however, 137 were considered to be of transferrable quality.
The distributions of SG-adjusted urinary metabolite concentrations for male and female partners are reported in Table II . For both male and female partners, 13 of the 15 of the measured urinary phthalate metabolite concentrations (MEHP, MEHHP, MEOHP, MECPP, MBP, MBzP, MiBP, MHiBP, MEP, MCPP, MCNP, MCOP and MMP) had detection frequencies ranging from 75% to 100%. Urinary MHBP was detected in 74% of male samples and 65% of female samples, while urinary MNP was detected in 62% of male samples and 57% of female samples. Concentrations of MHINCH and MCOCH, metabolites of the phthalate alternative DINCH, were only detected in 43% and 16% of couples' samples, respectively, and were fitted as dichotomous predictor variables, above and below the LOD, in subsequent regression analyses. Compared to male partners, female partners had higher urinary concentrations for the four metabolites of DEHP (MEHP, MEHHP, MEOHP and MECPP) and MCOP, MCNP, MHiBP, MHBP and MEP (P < 0.05).
In sex-specific and couple-level multivariate models, male or female urinary concentrations of phthalate and DINCH metabolites were not found to be associated with fertilization (Supplementary data, Table SI ). In sex-specific models, there were no significant associations between urinary biomarkers and embryo quality at the cleavage stage (Table III) .
However, after the inclusion of partners' metabolite concentrations and age in the model, there was a statistically significant positive association between male urinary MEP concentrations and high-quality cleavage stage embryos (OR = 1.20, 95% CI: 1.01-1.43). Table IV presents the associations between urinary biomarkers and high-quality embryos at the blastocyst stage in sex-specific and couplelevel multivariate analyses. Among male partners, there were statistically significant inverse associations between urinary concentrations of MBzP (OR = 0.58, 95% CI: 0.42-0.82), MBP (OR = 0.66, 95% CI: 0.53-0.82), MHBP (OR = 0.37, 95% CI: 0.19-0.75), MMP (OR = 0.63, 95% CI: 0.46-0.87) and MCOCH (OR = 0.34, 95% CI: 0.13-0.90) and high blastocyst quality. In couple-level models with adjustment for female age and female metabolite concentrations, the significant inverse associations between male urinary metabolite concentrations and high blastocyst quality largely persisted: MBzP (OR = 0.55, 95% CI: 0.36-0.84), MBP (OR = 0.55, 95% CI: 0.42-0.73), MHBP (OR = 0.37, 95% CI: 0.18-0.76) and MMP (OR = 0.39, 95% CI: 0.26-0.60); however, the estimates for MCOCH became borderline significant (OR = 0.21, 95% CI: 0.04-1.03; Table IV) . In both models, male urinary MEHP concentrations were associated with a >40% decrease in odds of high blastocyst quality, but it did not reach statistical significance in either model (P = 0.08 and 0.05 in sex-specific and couple-level models, respectively). In sex-specific models, female urinary concentrations of MHiBP were positively associated with high blastocyst quality (OR = 1.86, 95% CI: 1.01-3.4); however, this association did not reach statistical significance in couple-level models after adjusting for male age and male urinary MHiBP concentrations (OR = 2.00, 95% CI: 0.95-4.17). Conversely, female urinary concentrations of MMP (OR = 2.43, 95% CI: 1.23-4.79) and MCOCH (OR = 2.51, 95% CI: 1.02-6.14) were found to be positively associated with high blastocyst quality in the couple-level models with adjustment for male age and urinary metabolite concentrations but not in the sex-specific models.
When considering transferrable blastocyst quality (Table V) , the couple-level model estimates for male urinary concentrations of MBzP (OR = 0.70, 95% CI: 0.48-1.01), MBP (OR = 0.67, 95% CI: 0.43-1.03), MHBP (OR = 0.41, 95% CI: 0.21-0.80), MMP (OR = 0.72, 95% CI: 0.52-1.00) and MCOCH (OR = 0.41, 95% CI: 0.19-0.88) were all slightly attenuated compared to estimates from models of high-quality blastocysts, but all remained either statistically significant or borderline significant (P < 0.07). However, male urinary concentrations of MEHP were not associated with transferrable blastocyst quality in either sexspecific or in couple-level models. In contrast to the results for fertilization and cleavage stage embryos, male urinary concentrations of MEP were not associated with increased high (OR = 0.69, 95% CI: 0.44-1.08) or transferrable (OR = 1.06, 95% CI: 0.89-1.26) blastocyst quality. Female urinary concentrations of MHiBP (OR = 1.56, 95% CI: 1.00-2.43) and MNP (OR = 1.54, 95% CI: 1.14-2.09) were positively associated with transferrable blastocyst quality in the sex-specific models; however, in couple-level models accounting for male age and metabolite concentrations, only MNP remained statistically significant (OR = 1.74, 95% CI: 1.25-2.42).
A series of sensitivity analyses were conducted to validate the observed associations between male urinary metabolites and blastocyst quality. Sensitivity analyses were not performed on the DINCH metabolites due to small number of partners with detectable urinary concentrations. Of the 15 phthalate metabolites, 11 were correlated between couples-3 inversely and 8 positively (Supplementary data most quartiles of male urinary MEHP, MBP, MHBP and MBzP concentrations were inversely associated high blastocyst quality (Fig. 1) . Restriction of analyses to mature oocytes, fertilized oocytes, embryos of sufficient quality to be cultured past the cleavage stage or oocytes from nonsmokers did not appreciably alter the model estimates (Supplementary data, Table SIV) . Similarly, inclusion of other variables that did not meet the criteria for covariate selection, such as BMI, race, smoking and alcohol use, did not appreciably alter the effect estimates (data not shown). Finally, to cross-validate our model fit, we used Poisson regression and mixed models logistic regression approaches, which produced similar estimates and trends compared to our GEE models (data not shown).
Discussion
In our prospective study of 761 oocytes from 50 couples undergoing IVF, we observed that select male urinary concentrations of phthalate and phthalate replacement metabolites were inversely associated with high embryo quality. Specifically, male urinary concentrations of MBzP, MBP, MHBP, MMP and MCOCH were associated with a pronounced decrease in blastocyst quality; however, no such associations were observed during the cleavage stage for either male or female metabolites. Such results suggest that the negative influences of paternal phthalates on embryo quality arose after Day 3: during the transition from the cleavage to blastocyst stage of embryo development. It is noteworthy to mention that zygotic genome activation occurs during this transition. Select female metabolites were associated with increased odds of high blastocyst quality, but the lack of consistency hinders the reliability and interpretability of these results. Overall, our observed inverse association of male preconception phthalate and phthalate alternative metabolites with blastocyst quality supports the growing evidence that the preconception paternal environmental health may contribute to reproductive potential. The findings from our study are supported by the previous work from the LIFE study (Buck Louis et al., 2011) , which reported that preconception male urinary concentrations of MMP, MBP and MBzP were inversely associated with couples' fecundity as measured by time to pregnancy (TTP) (Buck Louis et al., 2014) . The association between male preconception phthalates and increased TTP is a broad observation and is likely facilitated by unobserved intermediate clinical end points throughout pregnancy such as altered embryo development, decreased chances of implantation and increased chances of pregnancy loss. While the LIFE study could not observe some of these early life end points, the EARTH study of 211 couples totalling 406 treatment cycles recently reported that higher male preconception urinary concentrations of MCPP and MCOP were associated with decreased odds of implantation and live birth following IVF, while MBP was associated with decreased odds of live birth following IUI but not IVF (Dodge et al., 2015) . In agreement with our findings, male urinary phthalate metabolite concentrations in the EARTH study were not associated with fertilization rate or embryo quality at Day 3; however, it must be noted that blastocyst quality data were unavailable because the majority of the EARTH participants received embryo transfers on Day 3.
One advantage of our SEEDS cohort of couples undergoing fertility treatment was the investigation of early embryo development through blastocyst development. We found that five male concentrations of phthalates or phthalate alternatives metabolites, including all three aforementioned metabolites found to be associated with decreased fecundity in the LIFE study, were associated with decreased blastocyst quality, resulting in a lower odds of high-quality transferrable embryos. However, in contrast to the findings that male urinary MCNP and MCOP concentrations were associated with decreased odds of implantation and live birth in the EARTH cohort, we found no such associations between urinary concentrations of these metabolites and embryo development. Such discrepancies in findings may be due to a smaller sample in our study and require further investigation. Finally, male urinary MEP concentrations were associated with increased embryo quality at the cleavage stage in our study, but this association was not observed at the blastocyst stage. This particular observation may be either spurious or transient. Together with previous reports from the LIFE and EARTH cohorts, our results add to the growing body of literature suggesting that preconception male phthalate exposures are likely contributors to adverse reproductive health outcomes.
IVF laboratory protocols bypass direct exposure of female partners to seminal fluid and other paternal inputs; therefore, the only avenue for male environmental contributions to embryo development is through acquired characteristics of sperm. Therefore, our observed inverse association between male urinary metabolite concentrations of phthalates and blastocyst morphology implies such a sperm-mediated effect. Although our results do not show altered embryo development associated with urinary metabolites at Day 3, it is possible that the molecular changes associated with phthalates and phthalate alternatives were too subtle to be detected morphologically during these early cleavage stages, and that such early molecular changes manifest at the morphological level during later stages of development. Alternatively, it is possible that urinary phthalates and phthalate alternatives are not associated with embryo development until after Day 3. Our observed associations with blastocysts, but not cleavage stage embryos, coincides with the timing of the embryonic genome activation (EGA). At the four-to eight-cell stage, corresponding to Day 3 of human embryo development (Niakan et al., 2012) , the human embryos are in a stage of relative transcriptional silence, relying on maternally derived products for the first cell divisions (Baroux et al., 2008; Zhang and Smith, 2015) . EGA facilitates a transition from maternal to embryonic control, which includes the degradation of maternal mRNAs and major changes in expression of histone isoforms, histone modifications, chromatin structure (Latham and Schultz, 2001 ) and DNA methylation (Messerschmidt et al., 2014) . In this scenario, the timing of the observed morphological changes may be due to altered features of the paternal genome or factors that would otherwise govern the paternal genome. It has been hypothesized that paternal epigenetic inheritance of factors governing DNA expression is important for embryogenesis (Gannon et al., 2014) and is modifiable by the male environment (Wu et al., 2015) . Furthermore, studies have reported that select phthalates, including those that are inversely associated with embryo quality in our study, have been associated with sperm DNA damage and abnormalities in humans (Duty et al., 2003; Hauser et al., 2007; Jurewicz et al., 2013; Wang et al., 2016) .
In recent years, certain phthalates have been substituted for newer phthalate compounds and phthalate alternative compounds due to their potential negative impacts on human health (Zota et al., 2014) . The detection frequency and concentrations of urinary metabolites of DiNP and DiDP, two relatively new phthalate compounds, have increased dramatically over the last decade. For example, the creatinine-corrected mean urinary concentration of MCOP, a metabolite of DiNP, has risen from 5.26 µg/g creatinine in 2005-2006 to 22.4 µg/ng creatinine in according to NHANES data (CDC, 2015 . Similarly, DINCH was commercialized in 2002 and has been detected in increasingly higher numbers of the general US population since 2007 (Silva et al., 2015) . While most of the metabolites of the new phthalates and phthalate alternatives were not found to be associated with embryo quality, we observed that having detectable levels of MCOCH in the male partner's urine was associated with nearly 80% decreased odds of high blastocyst quality and 60% decreased odds of transferable blastocyst quality. However, we must note only 16% of male partners, contributing to 129 oocytes out of 761, had detectable levels of MCOCH; therefore, these estimates need to be interpreted cautiously and replicated in other studies.
To our knowledge, our study was the first prospective study to assess the associations between paternal exposure to phthalates and phthalate alternatives and embryo quality in humans. The urine samples were collected on the day of sperm donation and embryo retrieval and are representative of parental phthalate exposures prior to conception, eliminating any potential temporal bias. Unlike previous studies using couple-level data, our study employed embryo-level data, which allowed us to account for inter-individual differences that likely exist when considering the potential of oocytes and sperm to form high-quality embryos. We also recognize some limitations of our study. First, our modest sample size only included 50 couples contributing one cycle each. However, data were collected on over 700 individual oocytes, including over 400 embryos. In addition, non-differential misclassification of exposure remains a concern given the single-spot urine collection and the short half-life of phthalates, although such non-differential misclassification of exposures will likely bias the results towards the null. Furthermore, previous studies suggest that a single-spot urine is sufficient to represent phthalate exposure over several months (Hauser et al., 2004; Teitelbaum et al., 2008) .
Conclusion
Results from our prospective study of 50 couples undergoing IVF show that male urinary metabolite concentrations of select phthalates and phthalate alternatives are inversely associated with high and transferrable quality blastocysts. Our study provides the first data demonstrating associations between phthalate and phthalate alternatives and embryo development, in a critical step towards our understanding of the paternal preconception contributions to reproductive success. Future studies are needed to investigate the long-term effects of altered embryo development and elucidate the mechanism by which paternal preconception exposure to phthalates and phthalate alternatives affects embryo development.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/. Figure 1 Odds ratios for high-quality blastocysts status (Day 5) by quartiles of male urinary phthalate concentrations, adjusted for age of male and female partners, male infertility status, embryo grade at cleavage stage and female urinary metabolite concentrations.
